Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-24T15:06:10.494Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparison of the Patient-Borne Costs of Therapy with Gamma Globulin given at the Hospital or at Home

Published online by Cambridge University Press:  10 March 2009

Ann Gardulf ,
Gudrun Möller  and
Egon Jonsson
Ann Gardulf
Affiliation:
Huddinge University Hospital
Gudrun Möller
Affiliation:
The Swedish Council on Technology Assessment in Health Care
Egon Jonsson
Affiliation:
The Swedish Council on Technology Assessment in Health Care
Get access Rights & Permissions [Opens in a new window]

Abstarct

The major aim of this study was to estimate and compare the patient-borne costs of lifelong subcutaneous gamma globulin therapy at the hospital and at home. Thirty patients were included and the data were collected with a questionnaire. The introduction of self-therapy at home reduced the total yearly costs by approximately 50% and the out-of-pocket expenses for the palients by 85%.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 11 , Issue 2 , Spring 1995 , pp. 345 - 353
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bielory, L., & Long, G. C.Home infusion therapy: Comparison of costs for intravenous immunoglobulin. New Jersey Medicine, 1993, 90, 512–15.Google ScholarPubMed
2.Björkander, L., Bake, B., & Hanson, L-Å.Primary hypogammaglobulinaemia: Impaired lung function and body growth with delayed diagnosis and inadequate treatment. European Journal of Respiratory Disease, 1984, 65, 529–36.Google ScholarPubMed
3.Brennan, V. M.Home self-infusion of IV immunoglobulin. Nursing Standard, 1991, 5, 37–39.CrossRefGoogle Scholar
4.Buckley, R. H., & Schiff, R. I.The use of intravenous immune globulin in immunodeficiency diseases. New England Journal of Medicine, 1991, 325, 110–17.Google ScholarPubMed
5.Chapel, H., Brennan, V., & Delson, E.Immunoglobulin replacement therapy by self-infusion at home. Clinical and Experimental Immunology, 1988, 73, 160–62.Google ScholarPubMed
6.Cohen, D. R., & Henderson, J. B.Health, prevention and economics. New York: Oxford University Press, 1988.Google Scholar
7. Consensus on IVIG [editorial]. Lancet, 1990, i, 470–72.Google Scholar
8.Cumming, J. E., & Weaver, F. M.Cost-effectiveness of home care. Clinics in Geriatric Medicine, 1991, 7, 865–74.CrossRefGoogle Scholar
9.Drummond, M. F.Principles of economic appraisal in health care, 6th ed.New York: Oxford University Press, 1989.Google Scholar
10.Fasth, A.Primary immunodeficiency disorders in Sweden: Cases among children, 1974–1979. Journal of Clinical Immunology, 1982, 2, 86–92.CrossRefGoogle ScholarPubMed
11.Gardulf, A., Andersen, V., Bjöorkander, J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet, 1995, 341, 365–69.Google Scholar
12.Gardulf, A., Björvell, H., Andersen, V., et al. Lifelong treatment with gammaglobulin for patients with primary antibody deficiencies: The patients’ experiences of subcutaneous self-infusions and home therapy. Journal of Advanced Nursing, 1995, 21, in press.CrossRefGoogle Scholar
13.Gardulf, A., Björvell, H., Gustafson, R., et al. Safety of rapid subcutaneous immune globulin infusions in patients with primary antibody deficiency. Immunodeficiency, 1993, 4, 81–84.Google ScholarPubMed
14.Gardulf, A., Hammarström, L., & Smith, C. I. E.Home treatment of hypogammaglobulinaemia with subcutaneous immune globulin by rapid infusion. Lancet, 1991, 338, 162–66.Google ScholarPubMed
15.Harrison, A. J.The economics of transport appraisal. London: Croom Helm, 1974.Google Scholar
16.Hosking, C. S., & Robertson, D. M.Epidemiology and treatment of hypogammaglobulinemia. Birth Defects, 1983, 19, 223–27.Google ScholarPubMed
17.Mazzuca, S.Does patient education in chronic disease have therapeutic value? Journal of Chronic Disease, 1982, 35, 521–29.CrossRefGoogle ScholarPubMed
18.Ochs, H. D., Lee, M. L., Fisher, S. H., et al. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. Journal of Infectious Diseases, 1987, 156, 652–54.CrossRefGoogle ScholarPubMed
19.Official Statistics of Sweden. Statistical yearbook of Sweden, 1994. Stockholm: Statistics Sweden, 1993.Google Scholar
20.Remvig, I., Andersen, V., Hansen, N. E., & Karle, H.Prophylactic effect of self administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: A triple-blind cross-over study comparing P-IgG levels of 3g 1-1 versus 6g I- 1. Journal of Internal Medicine, 1991, 229, 73–77.CrossRefGoogle Scholar
21.Smith, C. I. E., Hammarström, L., Evengård, B., Gardulf, A., Björkander, J.Upprepade infektioner bör föranleda utredning angående primär immunbrist. Lakartidningen (Stock holm), 1992, 89, 2593–97 (Abstract in English).Google Scholar
22. Vägverket. Objektanalys 16: Effektkatalog väg-och gatuinvesteringar. Borlänge, Sweden: Vägverket, 1989, 169–71.Google Scholar